Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Ptc Therapeutics (PTCT) over the last 6 years, with Dec 2024 value amounting to $76.8 million.

  • Ptc Therapeutics' Shares Outstanding (Diluted Average) rose 2.68% to $76.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76.8 million, marking a year-over-year increase of 2.68%. This contributed to the annual value of $76.8 million for FY2024, which is 2.68% up from last year.
  • As of FY2024, Ptc Therapeutics' Shares Outstanding (Diluted Average) stood at $76.8 million, which was up 2.68% from $74.8 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Shares Outstanding (Diluted Average) peaked at $76.8 million during FY2024, and registered a low of $66.0 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $74.5 million, with a median of $74.8 million in 2023.
  • Data for Ptc Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increased of 12.17% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Shares Outstanding (Diluted Average) stood at $66.0 million in 2020, then climbed by 6.72% to $70.5 million in 2021, then rose by 1.79% to $71.7 million in 2022, then climbed by 4.34% to $74.8 million in 2023, then increased by 2.68% to $76.8 million in 2024.